Our Clinician Scientists Profile: Svenja Nölting

Svenja Nölting, Clinician Scientist, Adrenal Research CRC/TRR205

Dr. med. Svenja Nölting

Medical Clinic and Policlinic IV,
Endocrinology, Endocrine Tumors,
Klinikum der LMU, Munich      

State examination: 2008, Ludwig-Maximilians-Universität München               

Promotion: Identification of potential molecular mechanisms of the neuroprotective effect of the prionprotein in the murine ischaemic model. Institut für Neuropathologie und Prionenforschung, Ludwig-Maximilians-Universität München, 2009                                     

Research Theme: Molecular targeted therapies in neuroendocrine tumors, pheochromocytoma, paragangliomas- overcoming resistance with combined therapie and drug screening in human primary cultures in pheochromocytoma.

CRC/TRR 205 projects:  
Linking cell line PPGL model systems to clinical datasets – Nicole Bechmann
Mice PPGL model systems & translation to the clinic – Jens Pietzsch, Christian Ziegler


The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.b Aristizabal Prada ET, Spoettl G, Maurer J, Lauseker M, Koziolek E, Schrader J, Grossman AB, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S.Endocr Relat Cancer. 2018 Jun 12. pii: ERC-18-0159. doi: 10.1530/ERC-18-0159. [Epub ahead of print] PMID: 29895527

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PMID: 28800359

Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.
Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K. Endocrinology. 2014 Jul;155(7):2377-90. doi: 10.1210/en.2014-1027. Epub 2014 Apr 24. PMID: 24762141

Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Nölting S, Garcia E, Alusi G, Giubellino A, Pacak K, Korbonits M, Grossman AB. J Mol Endocrinol. 2012 Jul 25;49(2):79-96. doi: 10.1530/JME-12-0028. Print 2012 Oct. PMID: 22715163

Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.
Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Lancet Diabetes Endocrinol. 2017 Dec 8. pii: S2213-8587(17)30401-1. doi: 10.1016/S2213-8587(17)30401-1. [Epub ahead of print] Review. PMID: 29229497


  • 11/2010-11/2012            DFG- scholarship
  • 04/2014-05/2017            Novartis Young Investigator funding (YING- Programm)
  • 07/2014-12/2015            scholarship of the FöFoLe LMU München
  • 12/2014-12/2015            Curt-Bohnewand-Stiftung
  • 03/2017                           ENETS travel- scholarship zum Young Investigator Symposium
  • 07/2017-06/2018    Gerok Forschungsstelle [Clinician Scientist Programm der deutschen Forschungsgemeinschaft (DFG)]
  • 05/2018- 04/2020          Novartis Young Investigator funding (YING-Programm)